Zephyr AI Appoints Allen Hodge as Chief Commercial Officer

TYSONS, Va.--(BUSINESS WIRE)--Zephyr AI, Inc. (“Zephyr AI”), a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery precision medicine and predictive analytics has announced the appointment of Allen Hodge as Chief Commercial Officer. Hodge brings more than two decades of experience in building commercial organizations to this role. Prior to joining Zephyr AI, Hodge served as Senior Vice President and U.S. General Manager at BioCryst Pharmaceuticals, delivering a successful launch of Orladeyo for patients with hereditary angioedema.

At Zephyr AI, Hodge provides senior leadership and strategic vision to support the company’s commercial efforts. Hodge oversees business development, strategic partnerships, and the commercialization of tools and products.

“The Zephyr AI team is poised to transform the way that the healthcare industry approaches drug discovery, development, and predictive analytics,” said Hodge, Chief Commercial Officer of Zephyr AI. “I’m extremely impressed by the team and the body of work that has already been accomplished. I am eager to lead the continued growth of the company and its efforts to propel AI-driven precision medicine and predictive analytics forward in the most disruptive way possible.”

Before BioCryst, Hodge worked as Vice President of U.S. Oncology Sales at Array Biopharma, which was acquired by Pfizer in 2019. Hodge led the sales organization that delivered the successful launch of Braftovi + Mektovi for patients with BRAF-mutant melanoma. Earlier in his career, Hodge served as a Regional Sales Director in hematology and oncology at Celgene, Inc, and as a Zone Director for Shire Pharmaceuticals (formerly ViroPharma, Inc) in ultra-rare disease. In addition, he has held various commercial roles over his more than 20+ year career to include sales, training, marketing, operations, and sales leadership.

“As we enter into our next phase of evolution and growth as a company, it is incredibly exciting to welcome Allen to the Zephyr AI team,” said David L. Morgan II, CEO of Zephyr AI. “The passion, energy, and expertise he brings to the role are unmatched, and his unique perspective will help ensure our success as we pursue our mission to build tools and products that will lead to the development of new therapies and novel indications of existing drugs to drastically improve patient outcomes while significantly lowering the total cost of care.”

ABOUT ZEPHYR AI

Zephyr AI is a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery and precision medicine. Through partnerships and proprietary data, Zephyr AI is curating the world’s most comprehensive healthcare dataset and marrying it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support both patients and providers and fuel ongoing research. At Zephyr AI, our mission-focused team of world-class software engineers and biologists leverage big data and cutting-edge technology to derive transformational insights and build enduring partnerships that will revolutionize the treatment of cancer, diabetes, and other diseases. Visit us at zephyrai.bio and follow us on Twitter, Instagram, and LinkedIn.

ABOUT RED CELL PARTNERS

Red Cell Partners is an incubation firm building rapidly-scalable technology-led companies that are bringing revolutionary advancements to market in healthcare and national security. United by a shared sense of duty and deep belief in the power of innovation, Red Cell is developing powerful tools and solutions to address our Nation’s most pressing problems. Visit us at redcellpartners.com and follow us on Twitter, Instagram, and LinkedIn.